COMP <GO>
NATR vs JNJ // EV/EBITDA & P/E VALUATION
Nature's Sunshine Products Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NATR 5
— JNJ 6
▲ EV/EBITDA & P/E VALUATION LEADER: NATR
LAST: $12.25 (-0.24%) • MKT CAP: $216.1M
valuation
4.0x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NATR VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NATR | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 72.40% | 67.90% | +4.50 | NATR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 28.90% | 25.50% | +3.40 | NATR | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 4.0x | 18.5x | -14.50 | NATR | /valuation <GO> |
| Free Cash Flow Yield | 13.35% | 2.97% | +10.38 | NATR | /fcf-yield <GO> |
| Operating Margin | 5.20% | 34.70% | -29.50 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 4.10% | 28.50% | -24.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 6.00% | -0.30 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.33 | 5.59 | -1.26 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 62.1 | -20.34 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.3x | 23.0x | -12.70 | NATR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $216.1M | $662.49B | -$662.28B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NATR REV | JNJ REV | NATR GROSS % | JNJ GROSS % | NATR FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $480.1M | $94.19B | 72.4% | 67.9% | $28.8M | $19.70B |
| FY 2024 | $454.4M | $88.82B | 71.5% | 69.1% | $14.3M | $19.84B |
| FY 2023 | $445.3M | $85.16B | — | — | $41.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NATR // BETA —
JNJ // BETA 1.08